The response of intravitreal bevacizumab in the treatment of intraocular neovascularization

The response of intravitreal bevacizumab in the treatment of intraocular neovascularization - The effect of intravitreal bevacizumab in the treatment of intraocular neovascularization

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009389

Enrollment

Registered

2012-12-10

Start date

2012-12-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular neovascularization

Interventions

Intravitreal injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Finding rubeosis, retinal or choroidal neovascularization, and vision loss.

Exclusion criteria

Exclusion criteria: Cr>3.0mg/dL unstable angina malignant arhythmia pregnant female

Design outcomes

Primary

Measure	Time frame
visual acuity, fundus examination including FA, IA and optical coherence tomography(OCT) , number of intravitreal injection	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026